IRIS

Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)

CASRN 101-68-8, 9016-87-9

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (23 pp, 170 K)
Not assessed under the IRIS Program.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (23 pp, 170 K) last updated: 02/07/1998

System RfC (mg/m3) Basis PoD Composite UF Confidence
Nervous, Respiratory 6 x 10-4 Hyperplasia of olfactory epithelium BMC10 (HEC): 6 x 10-2
mg/m3
100 Medium
Nervous, Respiratory 6 x 10-4 Hyperplasia of olfactory epithelium BMC10 (HEC): 6 x 10-2
mg/m3
100 Medium

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (23 pp, 170 K) last updated: 02/07/1998

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Under U.S. EPA's 1996 Proposed Guidelines for Carcinogen Risk Assessment, the carcinogenic potential of MDI/PMDI would be characterized as "cannot be determined," but for which there is suggestive evidence that raises concern for carcinogenic effects.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (23 pp, 170 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (23 pp, 170 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.